Sponsor Pipeline

TransThera Sciences (Nanjing), Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
2
Phase 3
2
Disease Areas
Active Trials by Phase
Phase 3
2
Phase 2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07328919 Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients… Intrahepatic Cholangiocarcinoma (Icc) Not Yet Recruiting
NCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in… Cholangiocarcinoma Active, Not Recruiting
Phase 2
NCT07498478 Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in… Breast Cancer Recruiting
NCT06057571 Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or… Cholangiocarcinoma Metastatic Active, Not Recruiting
Phase 1
NCT05683717 A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With… B-Cell Malignancies Recruiting
Disease Areas
Cholangiocarcinoma (3) Breast Cancer (1)
Get alerts when TransThera Sciences (Nanjing), Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free